Zang Li, Hao Haojie, Liu Jiejie, Li Yijun, Han Weidong, Mu Yiming
Department of Endocrinology, Chinese PLA General Hospital, Beijing, 100853 China.
Department of Molecular Biology, Institute of Basic Medicine, College of Life Science, Chinese PLA General Hospital, Beijing, 100853 China.
Diabetol Metab Syndr. 2017 May 15;9:36. doi: 10.1186/s13098-017-0233-1. eCollection 2017.
Type 2 diabetes mellitus (T2DM), which is characterized by the combination of relative insulin deficiency and insulin resistance, cannot be reversed with existing therapeutic strategies. Transplantation of insulin-producing cells (IPCs) was once thought to be the most promising strategy for treating diabetes, but the pace from the laboratory to clinical application has been obstructed due to its drawbacks. Mesenchymal stem cells (MSCs) harbor differentiation potential, immunosuppressive properties, and anti-inflammatory effects, and they are considered an ideal candidate cell type for treatment of DM. MSC-related research has demonstrated exciting therapeutic effects in glycemic control both in vivo and in vitro, and these results now have been translated into clinical practice. However, some critical potential problems have emerged from current clinical trials. Multi-center, large-scale, double-blind, and placebo-controlled studies with strict supervision are required before MSC transplantation can become a routine therapeutic approach for T2DM. We briefly review the molecular mechanism of MSC treatment for T2DM as well as the merits and drawbacks identified in current clinical trials.
2型糖尿病（T2DM）的特征是相对胰岛素缺乏和胰岛素抵抗并存，现有治疗策略无法逆转该病。胰岛素生成细胞（IPC）移植曾被认为是治疗糖尿病最有前景的策略，但由于其缺点，从实验室到临床应用的进程受到了阻碍。间充质干细胞（MSC）具有分化潜能、免疫抑制特性和抗炎作用，被认为是治疗糖尿病的理想候选细胞类型。与MSC相关的研究已在体内和体外血糖控制方面显示出令人兴奋的治疗效果，这些结果现已转化为临床实践。然而，目前的临床试验出现了一些关键的潜在问题。在MSC移植成为T2DM的常规治疗方法之前，需要进行多中心、大规模、双盲和有严格监督的安慰剂对照研究。我们简要回顾了MSC治疗T2DM的分子机制以及当前临床试验中发现的优缺点。
